278 related articles for article (PubMed ID: 30567972)
1. Effects of Oncogenic Gα
Lapadula D; Farias E; Randolph CE; Purwin TJ; McGrath D; Charpentier TH; Zhang L; Wu S; Terai M; Sato T; Tall GG; Zhou N; Wedegaertner PB; Aplin AE; Aguirre-Ghiso J; Benovic JL
Mol Cancer Res; 2019 Apr; 17(4):963-973. PubMed ID: 30567972
[TBL] [Abstract][Full Text] [Related]
2. Direct targeting of Gα
Annala S; Feng X; Shridhar N; Eryilmaz F; Patt J; Yang J; Pfeil EM; Cervantes-Villagrana RD; Inoue A; Häberlein F; Slodczyk T; Reher R; Kehraus S; Monteleone S; Schrage R; Heycke N; Rick U; Engel S; Pfeifer A; Kolb P; König G; Bünemann M; Tüting T; Vázquez-Prado J; Gutkind JS; Gaffal E; Kostenis E
Sci Signal; 2019 Mar; 12(573):. PubMed ID: 30890659
[TBL] [Abstract][Full Text] [Related]
3. Targeting primary and metastatic uveal melanoma with a G protein inhibitor.
Onken MD; Makepeace CM; Kaltenbronn KM; Choi J; Hernandez-Aya L; Weilbaecher KN; Piggott KD; Rao PK; Yuede CM; Dixon AJ; Osei-Owusu P; Cooper JA; Blumer KJ
J Biol Chem; 2021; 296():100403. PubMed ID: 33577798
[TBL] [Abstract][Full Text] [Related]
4. Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gα
Booth L; Roberts JL; Sander C; Lalani AS; Kirkwood JM; Hancock JF; Poklepovic A; Dent P
Cancer Biol Ther; 2019; 20(5):700-710. PubMed ID: 30571927
[TBL] [Abstract][Full Text] [Related]
5. Combined Inhibition of Gα
Hitchman TD; Bayshtok G; Ceraudo E; Moore AR; Lee C; Jia R; Wang N; Pachai MR; Shoushtari AN; Francis JH; Guan Y; Chen J; Chang MT; Taylor BS; Sakmar TP; Huber T; Chi P; Chen Y
Clin Cancer Res; 2021 Mar; 27(5):1476-1490. PubMed ID: 33229459
[TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis, and Evaluation of Small Molecule Gαq/11 Protein Inhibitors for the Treatment of Uveal Melanoma.
Ge Y; Shi S; Deng JJ; Chen XP; Song Z; Liu L; Lou L; Zhang X; Xiong XF
J Med Chem; 2021 Mar; 64(6):3131-3152. PubMed ID: 33715360
[TBL] [Abstract][Full Text] [Related]
7. Research in practice: Therapeutic targeting of oncogenic GNAQ mutations in uveal melanoma.
Gaffal E
J Dtsch Dermatol Ges; 2020 Nov; 18(11):1245-1248. PubMed ID: 32954611
[TBL] [Abstract][Full Text] [Related]
8. Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways.
Wu X; Li J; Zhu M; Fletcher JA; Hodi FS
Mol Cancer Ther; 2012 Sep; 11(9):1905-14. PubMed ID: 22653968
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and evaluation of quinazoline derivatives as Gαq/11 proteins inhibitors against uveal melanoma.
Fan G; Liu L; Ye J; Xiao W; Xiong XF
Bioorg Chem; 2024 Feb; 143():107005. PubMed ID: 38043397
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic Gq/11 signaling acutely drives and chronically sustains metabolic reprogramming in uveal melanoma.
Onken MD; Noda SE; Kaltenbronn KM; Frankfater C; Makepeace CM; Fettig N; Piggott KD; Custer PL; Ippolito JE; Blumer KJ
J Biol Chem; 2022 Jan; 298(1):101495. PubMed ID: 34919964
[TBL] [Abstract][Full Text] [Related]
11. Dual Inhibition of Histone Deacetylases and the Mechanistic Target of Rapamycin Promotes Apoptosis in Cell Line Models of Uveal Melanoma.
Patel RP; Thomas JR; Curt KM; Fitzsimmons CM; Batista PJ; Bates SE; Gottesman MM; Robey RW
Invest Ophthalmol Vis Sci; 2021 Sep; 62(12):16. PubMed ID: 34533562
[TBL] [Abstract][Full Text] [Related]
12. RasGRP3 Mediates MAPK Pathway Activation in GNAQ Mutant Uveal Melanoma.
Chen X; Wu Q; Depeille P; Chen P; Thornton S; Kalirai H; Coupland SE; Roose JP; Bastian BC
Cancer Cell; 2017 May; 31(5):685-696.e6. PubMed ID: 28486107
[TBL] [Abstract][Full Text] [Related]
13. Kinome profiling identifies MARK3 and STK10 as potential therapeutic targets in uveal melanoma.
Baqai U; Kurimchak AM; Trachtenberg IV; Purwin TJ; Haj JI; Han A; Luo K; Pachon NF; Jeon A; Chua V; Davies MA; Gutkind JS; Benovic JL; Duncan JS; Aplin AE
J Biol Chem; 2023 Dec; 299(12):105418. PubMed ID: 37923138
[TBL] [Abstract][Full Text] [Related]
14. IGF1R Inhibition Enhances the Therapeutic Effects of Gq/11 Inhibition in Metastatic Uveal Melanoma Progression.
Lapadula D; Lam B; Terai M; Sugase T; Tanaka R; Farias E; Kadamb R; Lopez-Anton M; Heine CC; Modasia B; Aguirre-Ghiso JA; Aplin AE; Sato T; Benovic JL
Mol Cancer Ther; 2023 Jan; 22(1):63-74. PubMed ID: 36223548
[TBL] [Abstract][Full Text] [Related]
15. Dysregulated GPCR Signaling and Therapeutic Options in Uveal Melanoma.
Chua V; Lapadula D; Randolph C; Benovic JL; Wedegaertner PB; Aplin AE
Mol Cancer Res; 2017 May; 15(5):501-506. PubMed ID: 28223438
[TBL] [Abstract][Full Text] [Related]
16. Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.
Ambrosini G; Pratilas CA; Qin LX; Tadi M; Surriga O; Carvajal RD; Schwartz GK
Clin Cancer Res; 2012 Jul; 18(13):3552-61. PubMed ID: 22550165
[TBL] [Abstract][Full Text] [Related]
17. Combined Mcl-1 and YAP1/TAZ inhibition for treatment of metastatic uveal melanoma.
Glinkina KA; Teunisse AFAS; Gelmi MC; de Vries J; Jager MJ; Jochemsen AG
Melanoma Res; 2023 Oct; 33(5):345-356. PubMed ID: 37467061
[TBL] [Abstract][Full Text] [Related]
18. ARF6 Is an Actionable Node that Orchestrates Oncogenic GNAQ Signaling in Uveal Melanoma.
Yoo JH; Shi DS; Grossmann AH; Sorensen LK; Tong Z; Mleynek TM; Rogers A; Zhu W; Richards JR; Winter JM; Zhu J; Dunn C; Bajji A; Shenderovich M; Mueller AL; Woodman SE; Harbour JW; Thomas KR; Odelberg SJ; Ostanin K; Li DY
Cancer Cell; 2016 Jun; 29(6):889-904. PubMed ID: 27265506
[TBL] [Abstract][Full Text] [Related]
19. MEK-ing the Most of It: Strategies to Co-target Gαq and MAPK in Uveal Melanoma.
Neelature Sriramareddy S; Smalley KSM
Clin Cancer Res; 2021 Mar; 27(5):1217-1219. PubMed ID: 33355300
[TBL] [Abstract][Full Text] [Related]
20. Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.
Chen X; Wu Q; Tan L; Porter D; Jager MJ; Emery C; Bastian BC
Oncogene; 2014 Sep; 33(39):4724-34. PubMed ID: 24141786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
